Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects

A review of randomized studies

V. Tullo, G. Bussone, S. Omboni, P. Barbanti, P. Cortelli, M. Curone, C. Peccarisi, C. Benedetto, D. Pezzola, D. Zava, G. Allais

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p

Original languageEnglish
JournalNeurological Sciences
Volume34
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2013

Fingerprint

Tryptamines
Migraine Disorders
zolmitriptan
Hypertension
Migraine with Aura
Therapeutics
Cross-Over Studies
Headache
Epilepsy
frovatriptan

Keywords

  • Almotriptan
  • Arterial hypertension
  • Frovatriptan
  • Migraine
  • Rizatriptan
  • Zolmitriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Cite this

Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects : A review of randomized studies. / Tullo, V.; Bussone, G.; Omboni, S.; Barbanti, P.; Cortelli, P.; Curone, M.; Peccarisi, C.; Benedetto, C.; Pezzola, D.; Zava, D.; Allais, G.

In: Neurological Sciences, Vol. 34, No. SUPPL. 1, 2013.

Research output: Contribution to journalArticle

Tullo, V. ; Bussone, G. ; Omboni, S. ; Barbanti, P. ; Cortelli, P. ; Curone, M. ; Peccarisi, C. ; Benedetto, C. ; Pezzola, D. ; Zava, D. ; Allais, G. / Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects : A review of randomized studies. In: Neurological Sciences. 2013 ; Vol. 34, No. SUPPL. 1.
@article{743956a054cc44339170acbe05e493a4,
title = "Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: A review of randomized studies",
abstract = "Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 {\%} NT, p",
keywords = "Almotriptan, Arterial hypertension, Frovatriptan, Migraine, Rizatriptan, Zolmitriptan",
author = "V. Tullo and G. Bussone and S. Omboni and P. Barbanti and P. Cortelli and M. Curone and C. Peccarisi and C. Benedetto and D. Pezzola and D. Zava and G. Allais",
year = "2013",
doi = "10.1007/s10072-013-1367-z",
language = "English",
volume = "34",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects

T2 - A review of randomized studies

AU - Tullo, V.

AU - Bussone, G.

AU - Omboni, S.

AU - Barbanti, P.

AU - Cortelli, P.

AU - Curone, M.

AU - Peccarisi, C.

AU - Benedetto, C.

AU - Pezzola, D.

AU - Zava, D.

AU - Allais, G.

PY - 2013

Y1 - 2013

N2 - Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p

AB - Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p

KW - Almotriptan

KW - Arterial hypertension

KW - Frovatriptan

KW - Migraine

KW - Rizatriptan

KW - Zolmitriptan

UR - http://www.scopus.com/inward/record.url?scp=84892544859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892544859&partnerID=8YFLogxK

U2 - 10.1007/s10072-013-1367-z

DO - 10.1007/s10072-013-1367-z

M3 - Article

VL - 34

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 1

ER -